Loading...

HALO HALOZYME THERAPEUTICS INC Capital Structure Changes 8-K Filing

HLZY

HL

HALOZYME THERAPEUTICS INC

(HALO)

2025 8-K

Financial Results Report

Annual Meeting Results

CFO Appointment

Bylaw Amendments

Management Change

Quarterly Earnings Report

Financial Guidance Update

Stock Grant Approval

Executive Departure

Convertible Notes Issued

Convertible Notes Offering

Credit Agreement Amendment

Management Change

Medicare Guidance Issued

Management Appointment

Merger Announcement

Merger Announcement

Financial Statements

Financial Statements

Management Change

Financial Results

Director Resignation

Financial Guidance

Q3 Financial Results

Financial Results

Financial Results

Financial Update

Financial Results

Delay in Tecentriq SC Launch

Results of Operations and F...

Financial Results

Annual Meeting of Stockholders

FDIC Closure of Silicon Val...

Financial Results

Appointment of Director

Financial Guidance for 2023

External Links:

On November 5, 2025, Halozyme Therapeutics amended its credit agreement to extend a revolving credit facility to $750 million, maturing on November 5, 2030. Additionally, the company plans to offer $650 million in convertible senior notes due 2031 and 2032, with an option for $100 million more.

AI Assistant

HALOZYME THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.